Impact of COVID-19 in allergen immunotherapy: An Italian survey.
Allergol Immunopathol (Madr)
; 50(5): 57-60, 2022.
Article
in English
| MEDLINE | ID: covidwho-2025812
ABSTRACT
Allergen immunotherapy (AIT) is a common treatment for patients with allergic asthma and allergic rhinoconjunctivitis. There is evidence that the COVID-19 pandemic could have altered the administration of AIT in patients in some countries, as the pandemic caused major limitations to healthcare access and delivery. The objective of this study was to evaluate the impact of the disruption imposed by the pandemic on the perceptions and administration of AIT therapies in Italy. An online survey was carried out among Italian allergists between 22 February 2021 and 12 April 2021. The results show that Italian physicians (N=66) did not consider that the COVID-19 pandemic presented an added risk to patients with allergic asthma or rhinitis receiving AIT. Although most treatments continued, there were reduced rates of AIT therapy initiations and sublingual AIT was favored over subcutaneous AIT.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Asthma
/
Sublingual Immunotherapy
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Allergol Immunopathol (Madr)
Year:
2022
Document Type:
Article
Affiliation country:
Aei.v50i5.595
Similar
MEDLINE
...
LILACS
LIS